HilleVax (NASDAQ:HLVX) Downgraded by Guggenheim to Neutral

Guggenheim downgraded shares of HilleVax (NASDAQ:HLVXFree Report) from a buy rating to a neutral rating in a research note issued to investors on Monday, Marketbeat reports.

A number of other research analysts also recently issued reports on the company. HC Wainwright restated a buy rating and set a $28.00 price target on shares of HilleVax in a research note on Friday, May 10th. JPMorgan Chase & Co. restated a neutral rating and set a $5.00 price target (down previously from $24.00) on shares of HilleVax in a research note on Monday. Six equities research analysts have rated the stock with a hold rating, According to MarketBeat.com, the company presently has an average rating of Hold and a consensus price target of $9.20.

Read Our Latest Stock Analysis on HLVX

HilleVax Price Performance

HLVX opened at $1.63 on Monday. The stock’s 50-day moving average price is $13.04 and its 200 day moving average price is $14.59. The company has a current ratio of 10.92, a quick ratio of 10.92 and a debt-to-equity ratio of 0.11. HilleVax has a 12-month low of $1.55 and a 12-month high of $20.22. The firm has a market cap of $81.04 million, a price-to-earnings ratio of -0.49 and a beta of 0.78.

HilleVax (NASDAQ:HLVXGet Free Report) last issued its quarterly earnings results on Thursday, May 9th. The company reported ($0.97) earnings per share for the quarter, missing the consensus estimate of ($0.84) by ($0.13). As a group, sell-side analysts expect that HilleVax will post -3.14 earnings per share for the current year.

Insider Activity

In other news, Director Aditya Kohli sold 6,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 22nd. The stock was sold at an average price of $14.73, for a total value of $88,380.00. Following the completion of the sale, the director now directly owns 764,878 shares of the company’s stock, valued at approximately $11,266,652.94. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold 12,898 shares of company stock valued at $193,766 in the last three months. 71.10% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On HilleVax

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Franklin Resources Inc. raised its holdings in HilleVax by 4.1% during the fourth quarter. Franklin Resources Inc. now owns 1,846,396 shares of the company’s stock worth $29,635,000 after purchasing an additional 71,938 shares during the last quarter. Catalys Pacific LLC acquired a new position in HilleVax during the fourth quarter worth $21,009,000. Adage Capital Partners GP L.L.C. acquired a new position in HilleVax during the third quarter worth $2,374,000. Swiss National Bank raised its holdings in HilleVax by 22.4% during the fourth quarter. Swiss National Bank now owns 38,200 shares of the company’s stock worth $613,000 after purchasing an additional 7,000 shares during the last quarter. Finally, abrdn plc acquired a new position in HilleVax during the fourth quarter worth $433,000. 86.42% of the stock is owned by institutional investors and hedge funds.

HilleVax Company Profile

(Get Free Report)

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.

Featured Articles

Analyst Recommendations for HilleVax (NASDAQ:HLVX)

Receive News & Ratings for HilleVax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HilleVax and related companies with MarketBeat.com's FREE daily email newsletter.